Solstice Capital
81 Washington St Ste 303, Salem, Massachusetts, 01970, United States
Overview
Solstice Capital seeks superior venture capital returns for its limited partners through investments in seed- and early-stage companies in the industry areas of alternative energy, education, the environment, life sciences and information technology. Solstice's unique assets give it a distinct advantage: a seasoned management team with over 90 years of experience in both venture investing and operations in high-growth companies an emphasis on positive impact investing the appropriate size fund for early-stage companies geographic diversification From its inception, Solstice has demonstrated its commitment to provide both capital and expert guidance to assist portfolio companies as they deal with the challenges and opportunities of growth. An early-stage, diversified, positive impact venture fund Solstice is committed to investing 50% of its capital in information technology and 50% in the following socially responsive investment categories: Alternative Energy The Environment Life Sciences Education
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Regenesis Biomedical
Participated · Series C · Jun 2011
Regenesis Biomedical develops and markets regenerative medicine products, primarily the Provant Therapy System, which uses pulsed radio frequency energy (PRFE) to reduce pain and edema in post-operative, superficial soft tissues. The company sells to acute care hospitals, long-term acute care hospitals, skilled nursing facilities and outpatient clinics. Led by President and CEO Virginia Rybski, Regenesis holds patents on its Provant system and actively markets the device. The company completed a Series C financing to support growth. Proceeds are intended to accelerate expansion of its sales team to broaden clinical adoption.
- HTG
Participated · Series D · Feb 2011
HTG, Inc. is a Tucson, Arizona-based provider of molecular technology solutions led by CEO TJ Johnson. Its core product is the qNPA™ molecular technology platform and a multi-plex gene expression testing platform for miRNA and mRNA measurement, translational medicine and diagnostic applications. The qNPA platform is in use at major academic and cancer research centers as well as by big pharma. The company closed the first tranche of a $15.7M Series D financing to support its growth. HTG intends to use the funding to drive adoption of its testing platform for validation and clinical applications across different therapeutic areas and to expand into new high-growth molecular diagnostic opportunities. The company also plans to hire additional personnel in 2011, including sales and marketing, operations and development scientists with diagnostics experience.
Team
Harry George
Co-Founder & Managing General Partner
Henry Newman
Co-Founder & General Partner
LinkedInFrederick B. Bamber
General Partner